Evidence map›Paper›PMID 29377200›Full record

ReviewAnnals of the New York Academy of Sciences2018

Precision medicine in diabetes: an opportunity for clinical translation.

Jordi Merino, Jose C Florez

Abstract readReview
In one paragraph

Review in Annals of the New York Academy of Sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Epigenetics in Precision Nutrition.Journal of personalized medicine · 2022
    Review
  9. Article
  10. Article
  11. The ongoing effect of diabetes during pregnancy and the impact on infants.The Lancet regional health. Western Pacific · 2020
    Article
  12. Paracrine signaling in islet function and survival.Journal of molecular medicine (Berlin, Germany) · 2020
    Review
  13. Utility of Precision Medicine in the Management of Diabetes: Expert Opinion from an International Panel.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
    Review
  14. The current state of omics technologies in the clinical management of asthma and allergic diseases.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2019
    Review
  15. Review
  16. Article
  17. Review
  18. Precision Medicine in Non Communicable Diseases.International journal of molecular and cellular medicine · 2019
    Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jordi MerinoDiabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0001-8312-1438
Jose C FlorezDiabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts.

Funding

Mentoring Investigators on the Clinical Translation of Genetic Discoveries in Type 2 DiabetesK24DK110550 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI FLOREZ, JOSE CARLOS · 2016 to 2020
$812k
NIDDK NIH HHS K24 DK110550
6 · The paper itself

Abstract

Metabolic disorders present a public health challenge of staggering proportions. In diabetes, there is an urgent need to better understand disease heterogeneity, clinical trajectories, and related comorbidities. A pressing and timely question is whether we are ready for precision medicine in diabetes. Some biological insights that have emerged during the last decade have already been used to direct clinical decision making, especially in monogenic forms of diabetes. However, much work is necessary to integrate high-dimensional explorations into complex disease architectures, less penetrant biological alterations, and broader phenotypes, such as type 2 diabetes. In addition, for precision medicine to take hold in diabetes, reproducibility, interpretability, and actionability remain key guiding objectives. In this review, we examine how mounting data sets generated during the last decade to understand biological variability are now inspiring new venues to clarify diabetes nosology and ultimately translate findings into more effective prevention and treatment strategies.

Indexed as

Precision MedicineTranslational Research, BiomedicalBiotransformationClinical Decision-MakingDatasets as TopicDiabetes MellitusDiabetes Mellitus, Type 2Genome-Wide Association StudyHumansHypoglycemic AgentsPhenotypeReproducibility of ResultsHypoglycemic Agentsdiabetesdiabetes heterogeneityomicsprecision medicine

Identifiers

PMID29377200
PMCPMC6686889

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.